Photocure ASA: Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 meeting in Boston
· 21.5% of patients with recurrence of bladder cancer would have been missed if BLFC with Cysview had not been used in the surveillance setting, which is highly significant (p<0.0001) · Photocure plans to file a supplemental NDA with FDA later this year Oslo, Norway, May 15[th], 2017: Photocure ASA (Photocure, PHO:OSE), today announced that new Phase 3 study results with Blue Light Flexible Cystoscopy (BLFC(TM)) with Hexvix[®]/Cysview[®* ]were presented during a late-breaking plenary session at the American Urological Association (AUA) Annual Meeting in Boston, Massachusetts on